News
TERN
5.71
+1.96%
0.11
Top 3 Health Care Stocks You'll Regret Missing In Q4
Benzinga · 2d ago
Terns Pharmaceuticals Appoints Heather Turner to Board of Directors, Ann E. Taylor Steps Down
Barchart · 3d ago
TERNS PHARMACEUTICALS APPOINTS HEATHER TURNER, J.D., TO BOARD OF DIRECTORS
Reuters · 3d ago
Press Release: Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
Dow Jones · 3d ago
Weekly Report: what happened at TERN last week (1111-1115)?
Weekly Report · 4d ago
Insiders Re-Evaluate Their US$5.05m Stock Purchase As Terns Pharmaceuticals Falls To US$556m
Simply Wall St · 5d ago
Terns Pharmaceuticals Reports Q3 Progress and Financials
TipRanks · 11/14 04:34
Promising Phase 1/2 Study and Strong Financials Drive Buy Rating for Terns Pharmaceuticals
TipRanks · 11/14 00:25
Terns Pharmaceuticals Is Maintained at Neutral by HC Wainwright & Co.
Dow Jones · 11/13 19:01
Terns Pharmaceuticals Price Target Raised to $7.50/Share From $5.50 by HC Wainwright & Co.
Dow Jones · 11/13 19:01
HC Wainwright & Co. Maintains Neutral on Terns Pharma, Raises Price Target to $7.5
Benzinga · 11/13 18:51
Terns Pharmaceuticals: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
TipRanks · 11/13 12:16
Hold Rating for Terns Pharmaceuticals Amid Awaited Data and Study Developments
TipRanks · 11/13 11:30
TERNS PHARMACEUTICALS, INC. <TERN.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $7.5 FROM $5.5
Reuters · 11/13 11:11
Terns Pharmaceuticals: Promising Oncology Developments and Strategic Pipeline Diversification Justify Buy Rating
TipRanks · 11/13 05:45
Press Release: Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates
Dow Jones · 11/12 21:05
Weekly Report: what happened at TERN last week (1104-1108)?
Weekly Report · 11/11 09:17
Weekly Report: what happened at TERN last week (1028-1101)?
Weekly Report · 11/04 09:18
Optimistic Outlook for Terns Pharmaceuticals: Potential of TERN-701 Amidst Market Opportunities
TipRanks · 11/01 10:08
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 10/31 15:37
More
Webull provides a variety of real-time TERN stock news. You can receive the latest news about Terns Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.